文献速递浆细胞疾病

石蒜碱通过抑制Wnt/β-catenin通路靶向多发性骨髓瘤干细胞样细胞

Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
PubMed 文献 · Br J Haematol · 2020-03-13

本研究探讨天然化合物石蒜碱对多发性骨髓瘤干细胞样细胞(MMSCs)的作用。结果显示石蒜碱通过降低β-catenin蛋白水平抑制Wnt/β-catenin通路,减少ALDH1+细胞,抑制骨髓瘤细胞增殖,并可克服硼替佐米(BTZ)引起的ALDH1+细胞增加,与BTZ联用具有协同抗骨髓瘤效应。在BTZ耐药细胞及原代CD138+浆细胞中亦观察到MMSC特征减少。

要点

  • 石蒜碱通过抑制Wnt/β-catenin通路减少ALDH1+ MMSCs。
  • 石蒜碱可逆转BTZ诱导的ALDH1+细胞增加,与BTZ协同。
  • 在BTZ耐药细胞及原代CD138+浆细胞中石蒜碱同样减少MMSC特征。

核心结论

  • 石蒜碱是有前景的靶向MMSCs的候选药物,单用或与BTZ联用可能成为MM治疗策略。

研究设计与样本

  • 研究使用骨髓瘤细胞系及患者来源细胞,评估石蒜碱对增殖及ALDH1+细胞的影响。

主要发现

  • 石蒜碱有效抑制细胞系或患者来源骨髓瘤细胞增殖,主要通过减少ALDH1+细胞。
  • 石蒜碱通过降低β-catenin蛋白水平抑制Wnt/β-catenin通路,减少MMSC群体。
  • 石蒜碱可克服BTZ治疗引起的ALDH1+细胞比例增加,BTZ与石蒜碱联用具有协同抗骨髓瘤细胞效应。
  • 在BTZ耐药骨髓瘤细胞及原代CD138+浆细胞中,石蒜碱同样减少MMSC特征。

临床怎么用

  • 石蒜碱单用或与BTZ联用可能作为靶向MMSCs、克服BTZ耐药的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is characterised by the proliferation and accumulation of malignant plasma cells in the bone marrow. Despite the progress in treatment over the last few years, MM remains incurable and the majority of patients relapse. MM stem-like cells (MMSCs) have been considered as the main reason for drug resistance and eventual relapse. Currently, therapeutic agents are not enough to eradicate MMSCs, and finding effective strategies to eradicate MMSCs may improve the outcome of patients. Here we showed that lycorine, a natural compound from the Amaryllidaceae species, effectively inhibits the proliferation of myeloma cells from cell lines or patients, mainly through decreasing ALDH1+ cells. Mechanistically, lycorine decreases the MMSC population through inhibition of the Wnt/β-catenin pathway by reducing the β-catenin protein level. Moreover, lycorine could overcome the increasing proportion of ALDH1+ cells caused by bortezomib (BTZ) treatment, and a combination BTZ and lycorine have a synergistic effect on anti-myeloma cells. Furthermore, we found a similar reduction of MMSC characteristics by lycorine in BTZ-resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, lycorine is a potential therapeutic strategy for MM treatments.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang H, Gong Y, Liang L, et al. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway. Br J Haematol. 2020. PMID: 32167591. doi:10.1111/bjh.16477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。